These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23988451)

  • 1. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma.
    Cervantes-Gomez F; Chen LS; Orlowski RZ; Gandhi V
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S317-29. PubMed ID: 23988451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
    Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
    Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.
    Chen LS; Redkar S; Taverna P; Cortes JE; Gandhi V
    Blood; 2011 Jul; 118(3):693-702. PubMed ID: 21628411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.
    Chen LS; Redkar S; Bearss D; Wierda WG; Gandhi V
    Blood; 2009 Nov; 114(19):4150-7. PubMed ID: 19734450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
    Natarajan K; Bhullar J; Shukla S; Burcu M; Chen ZS; Ambudkar SV; Baer MR
    Biochem Pharmacol; 2013 Feb; 85(4):514-24. PubMed ID: 23261525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical changes of salivary gland adenoid cystic carcinoma cells induced by SGI-1776.
    Hou X; Yu Y; Feng J; Wang J; Zheng C; Ling Z; Ge M; Zhu X
    Exp Cell Res; 2017 Mar; 352(2):403-411. PubMed ID: 28228352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel anti-adipogenic effect and mechanisms of action of SGI-1776, a Pim-specific inhibitor, in 3T3-L1 adipocytes.
    Park YK; Hong VS; Lee TY; Lee J; Choi JS; Park DS; Park GY; Jang BC
    Int J Mol Med; 2016 Jan; 37(1):157-64. PubMed ID: 26719859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
    Zheng J; Sha Y; Roof L; Foreman O; Lazarchick J; Venkta JK; Kozlowski C; Gasparetto C; Chao N; Ebens A; Hu J; Kang Y
    Cancer Lett; 2019 Jan; 440-441():1-10. PubMed ID: 30312729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.
    Mahalingam D; Espitia CM; Medina EC; Esquivel JA; Kelly KR; Bearss D; Choy G; Taverna P; Carew JS; Giles FJ; Nawrocki ST
    Br J Cancer; 2011 Nov; 105(10):1563-73. PubMed ID: 22015557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGI-1776, an imidazo pyridazine compound, inhibits the proliferation of ovarian cancer cells by inactivating Pim-1.
    Xie J; Bai J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 39(7):649-57. PubMed ID: 25080901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes.
    Mumenthaler SM; Ng PY; Hodge A; Bearss D; Berk G; Kanekal S; Redkar S; Taverna P; Agus DB; Jain A
    Mol Cancer Ther; 2009 Oct; 8(10):2882-93. PubMed ID: 19825806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors.
    Wurz RP; Sastri C; D'Amico DC; Herberich B; Jackson CLM; Pettus LH; Tasker AS; Wu B; Guerrero N; Lipford JR; Winston JT; Yang Y; Wang P; Nguyen Y; Andrews KL; Huang X; Lee MR; Mohr C; Zhang JD; Reid DL; Xu Y; Zhou Y; Wang HL
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5580-5590. PubMed ID: 27769621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.
    Foulks JM; Carpenter KJ; Luo B; Xu Y; Senina A; Nix R; Chan A; Clifford A; Wilkes M; Vollmer D; Brenning B; Merx S; Lai S; McCullar MV; Ho KK; Albertson DJ; Call LT; Bearss JJ; Tripp S; Liu T; Stephens BJ; Mollard A; Warner SL; Bearss DJ; Kanner SB
    Neoplasia; 2014 May; 16(5):403-12. PubMed ID: 24953177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Pim kinase inhibitor SGI-1776 and bendamustine in B-cell lymphoma.
    Yang Q; Chen LS; Neelapu SS; Gandhi V
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S355-62. PubMed ID: 24290221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition.
    Iqbal A; Eckerdt F; Bell J; Nakano I; Giles FJ; Cheng SY; Lulla RR; Goldman S; Platanias LC
    Oncotarget; 2016 May; 7(22):33192-201. PubMed ID: 27120806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
    Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
    Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.
    Batra V; Maris JM; Kang MH; Reynolds CP; Houghton PJ; Alexander D; Kolb EA; Gorlick R; Keir ST; Carol H; Lock R; Billups CA; Smith MA
    Pediatr Blood Cancer; 2012 Oct; 59(4):749-52. PubMed ID: 22052829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIM kinases 1, 2 and 3 in intracellular LIF signaling, proliferation and apoptosis in trophoblastic cells.
    Mary Photini S; Chaiwangyen W; Weber M; Al-Kawlani B; Favaro RR; Jeschke U; Schleussner E; Morales-Prieto DM; Markert UR
    Exp Cell Res; 2017 Oct; 359(1):275-283. PubMed ID: 28729093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells.
    Siu A; Virtanen C; Jongstra J
    Oncotarget; 2011 Dec; 2(12):1134-44. PubMed ID: 22193779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.